<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD with OASIS Tables v1.0 20120330//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing-oasis-article1.dtd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Deliv</journal-id><journal-id journal-id-type="iso-abbrev">Drug Deliv</journal-id><journal-id journal-id-type="publisher-id">IDRD</journal-id><journal-id journal-id-type="publisher-id">idrd20</journal-id><journal-title-group><journal-title>Drug Delivery</journal-title></journal-title-group><issn pub-type="ppub">1071-7544</issn><issn pub-type="epub">1521-0464</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6968257</article-id><article-id pub-id-type="pmid">31913730</article-id><article-id pub-id-type="doi">10.1080/10717544.2019.1709923</article-id><article-id pub-id-type="publisher-id">1709923</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Study on the cellular internalization mechanisms and <italic>in&#x000a0;vivo</italic>
anti-bone metastasis prostate cancer efficiency of the peptide T7-modified polypeptide
nanoparticles</article-title><alt-title alt-title-type="running-authors">Y. Gu et al.</alt-title><alt-title alt-title-type="running-title">Drug Delivery</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Gu</surname><given-names>Yongwei</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="author-notes" rid="FN0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Xinmei</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="author-notes" rid="FN0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Haiyan</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="author-notes" rid="FN0001">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Heyi</given-names></name><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Hang</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Sifan</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Youfa</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Yuansheng</given-names></name><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Xin</given-names></name><xref ref-type="aff" rid="AF0002">
<sup>b</sup>
</xref><xref ref-type="aff" rid="AF0004">
<sup>d</sup>
</xref><xref ref-type="corresp" rid="AN0002"/></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Jianming</given-names></name><xref ref-type="aff" rid="AF0001">
<sup>a</sup>
</xref><xref ref-type="aff" rid="AF0003">
<sup>c</sup>
</xref><xref ref-type="corresp" rid="AN0001"/></contrib><aff id="AF0001"><label>a</label><institution>Department of Pharmacy, Fujian University of
Traditional Chinese Medicine</institution>, Fuzhou, <country>China</country>; </aff><aff id="AF0002"><label>b</label><institution>School of Pharmacy, Second Military Medical
University</institution>, Shanghai, <country>China</country>; </aff><aff id="AF0003"><label>c</label><institution>Department of Pharmacy, Inner Mongolia Medical
University</institution>, Huhhot, <country>China</country>; </aff><aff id="AF0004"><label>d</label><institution>Shanghai Wei Er Biopharmaceutical Technology
Co., Ltd</institution>, Shanghai, <country>China</country></aff></contrib-group><author-notes><fn id="FN0001"><label>*</label><p>These authors contributed equally to this work.</p></fn><corresp id="AN0001"><bold>CONTACT</bold> Jianming Chen <email>chenjm0711@163.com</email><institution>Department of Pharmacy, Fujian University of Traditional Chinese
Medicine</institution>, Fuzhou 350108, <country>China</country></corresp><corresp id="AN0002">Xin Wu <email>wuxin007@126.com</email><institution>Shanghai Wei Er Biopharmaceutical Technology Co., Ltd.</institution>,
Shanghai 201707, <country>China</country></corresp></author-notes><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>8</day><month>1</month><year>2020</year></pub-date><volume>27</volume><issue>1</issue><fpage seq="14">161</fpage><lpage>169</lpage><history><date date-type="received"><day>28</day><month>11</month><year>2019</year></date><date date-type="rev-recd"><day>17</day><month>12</month><year>2019</year></date><date date-type="accepted"><day>24</day><month>12</month><year>2019</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s). Published by Informa UK Limited, trading as
Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>The Author(s)</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted
use, distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IDRD_27_1709923.pdf"/><abstract><title>Abstract</title><p>Bone-metastasis prostate cancer (BMPCa)-targeting gene therapy is gaining increasing
concern in recent years. The peptide T7-modified polypeptide nanoparticles for delivery
DNA (CRD-PEG-T7/pPMEPA1) was prepared as our previous study. However, the feasibility of
CRD-PEG-T7/pPMEPA1 for BMPCa treatment, the mechanisms underlying cellular uptake,
anti-BMPCa effect, and administration safety requires further research. LNCaP cells
treated with endocytosis inhibitors and excessive T7 under different culture condition
were carried out to investigate the mechanisms of cellular uptake of the
CRD-PEG-T7-pPMEPA1. A transwell assay was applied to evaluate the cell migration ability.
Besides, the tumor volume and survival rates of the PCa xenograft mice model were recorded
to estimate the anti-tumor effect. In addition, the weight profiles of the PCa
tumor-bearing mice, the blood chemistry, and the HE analysis of visceral organs and tumor
was conducted to investigate the administration safety of CRD-PEG-T7/pPMEPA1. The results
showed that PCa cellular uptake was decreased after treating with excessive free T7,
endocytosis inhibitors and lower incubation temperature. Besides, CRD-PEG-T7/pPMEPA1 could
inhibit the LNCaP cells chemotaxis and tumor growth. In addition, the survival duration of
the PCa tumor-bearing mice treating with CRD-PEG-T7/pPMEPA1 was significantly prolonged
with any systemic toxicity or damage to the organs. In conclusion, this research proposes
a promising stratagem for treatment BMPCa by providing the biocompatible and effective
carrier for delivery DNA therapeutic agents.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords</title><kwd>Gene therapy</kwd><kwd>bone-metastases prostate cancer</kwd><kwd>cellular internalization mechanisms</kwd><kwd>anti-tumor effect</kwd><kwd>administration safety</kwd></kwd-group><funding-group><award-group><funding-source><named-content content-type="funder-name">National Natural Science Foundation of
China</named-content><named-content content-type="funderidentifier">10.13039/501100001809</named-content></funding-source><award-id>81772749</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Shanghai Rising-Star Program</named-content></funding-source><award-id>18QB1400400</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Shanghai Qingpu District
Industry-University-Research Cooperation Development Fund Project</named-content></funding-source><award-id>QIUR 2019-5</award-id></award-group><award-group><funding-source><named-content content-type="funder-name">Shanghai Science and Technology Project of
Little Giant</named-content></funding-source><award-id>1902HX76600</award-id></award-group><funding-statement>This study was supported by the National Natural Science Foundation of
China [NO. 81772749], Shanghai Rising-Star Program [NO. 18QB1400400], Shanghai Qingpu
District Industry-University-Research Cooperation Development Fund Project [QIUR 2019-5],
and Shanghai Science and Technology Project of Little Giant
[1902HX76600].</funding-statement></funding-group><counts><fig-count count="7"/><table-count count="2"/><page-count count="9"/><word-count count="5056"/></counts></article-meta></front><body><sec id="s0001"><label>1.</label><title>Introduction</title><p>Prostate cancer (PCa) is the second death-leading malignancy in American men (Siegel
et&#x000a0;al., <xref rid="CIT0030" ref-type="bibr">2019</xref>). And about 90% of patients with PCa
develop BMPCa, bringing intolerable complications and uprising mortality (Bubendorf et&#x000a0;al.,
<xref rid="CIT0005" ref-type="bibr">2000</xref>; Halabi et&#x000a0;al., <xref rid="CIT0013" ref-type="bibr">2016</xref>; Nakazawa et&#x000a0;al., <xref rid="CIT0025" ref-type="bibr">2017</xref>; Nyquist &#x00026; Nelson, <xref rid="CIT0026" ref-type="bibr">2017</xref>).
There are some side effects on conventional aggressive surgery and chemotherapy. Especially,
bone-targeting agents including docetaxel&#x02009;&#x000b1;&#x02009;dadatinib, atrasentan were failed in preclinical
and phase II trial (Miyahira &#x00026; Soule, <xref rid="CIT0023" ref-type="bibr">2019</xref>).
Recently, gene therapy for metastatic prostate cancer gain desired development (Gu et&#x000a0;al.,
<xref rid="CIT0012" ref-type="bibr">2014</xref>; Wu et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2014</xref>).</p><p>For prostate cancer, TGF-&#x003b2; signaling pathway is closely related to cell proliferation,
which inhibits tumor cells growth in early-stage while promotes bone metastasis in later
stages (Donkor et&#x000a0;al., <xref rid="CIT0006" ref-type="bibr">2011</xref>). Studies have
demonstrated that TGF-&#x003b2; could upregulate the expression of the prostate transmembrane
protein androgen induced-1 (PMEPA1) which was encoded by the androgen-regulated gene
expressed in PCa (Singha et&#x000a0;al., <xref rid="CIT0031" ref-type="bibr">2010</xref>; Watanabe
et&#x000a0;al., <xref rid="CIT0034" ref-type="bibr">2010</xref>; Amalia et&#x000a0;al., <xref rid="CIT0001" ref-type="bibr">2019</xref>). Furthermore, clinical statistics revealed that
low expression of PMEPA1 led to bone metastases and dropped survival. In BMPCa patients,
PMEPA1 was decreased that regulates the tumor cells invasion, proliferation, and metastasis
(Fournier et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2015</xref>; Xu et&#x000a0;al., <xref rid="CIT0035" ref-type="bibr">2019</xref>). 20&#x02013;25% of metastatic PCa harbor defects in DNA
repair genes (Athie et&#x000a0;al., <xref rid="CIT0003" ref-type="bibr">2019</xref>). And gene
therapy for PCa is gaining great achievements through direct delivering DNA or RNA into
cancer cells.</p><p>We previously reported an effective BMPCa cells-targeting cationic polypeptide gene carrier
modified with peptide (T7, amino acid sequence: HAIYPRH) that could directly transfer
plasmid DNA (pDNA, pPMEPA1) into PCa cells, actively targeting to over expressing
transferrin receptors (TfR) in PCa cells (Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>). In addition, the polypeptide, (arginine (R)-aspartic (D) acid peptide
(RRRRRRRCDDDDDD)) known as R7D6 synthesized by F-mocsolid-phase synthesis method could
target to bone guiding with the aspartic acid short peptide sequence (de Kroon et&#x000a0;al., <xref rid="CIT0017" ref-type="bibr">2017</xref>). Then, under oxidizing conditions, R7D6 and
L-Cys&#x000b7;HCL react to form CRD (C: L-Cys, R: arginine; D: aspartic acid) that possessed
disulfide bonds. The polymers with disulfide bonds have the properties of biodegradation,
high stability, low biotoxicity, high transfection efficiency, and rapid intracellular drug
release (Lin et&#x000a0;al., <xref rid="CIT0019" ref-type="bibr">2006</xref>; Kim et&#x000a0;al., <xref rid="CIT0016" ref-type="bibr">2010</xref>). Then the CRD was modified with peptide T7 to
construct the final tumor-targeting gene delivery vector CRD-PEG-T7 (Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>). Interestingly, this vector could form
nanoparticles with pPMEPA1 at a certain N/P ratio. Therefore, we prepared CRD-PEG-T7 and
pPMEPA1 to form the CRD-PEG-T7/pPMEPA1 complexes. The cunning characteristics were as
follows: (1) the cationic polymer material could highly encapsulate gene; (2) the
polypeptide and the nanoparticles modified with peptide T7 could actively target to bone and
PCa cells; and (3) pPMEPA1 delivered by CRD-PEG-T7 could enhance anticancer effects
precisely.</p><p>Though the dual targetting vector of CRD-PEG-T7/pPMEPA1 was prepared in our previous study.
However, there remain elusion in terms of endocytosis mechanisms, anti-tumor effect and
safety evaluation. In this study, the endocytosis inhibitors were used to illustrate the
transmembrane mechanisms of the complexes. And, a transwell assay was applied to study the
inhibition effect of the modified nanoparticles in tumor cell migration. Besides,
pharmacodynamics was carried out to investigate the <italic>in&#x000a0;vivo</italic> anti-tumor
effect. Finally, the toxicity of systemic and organs was tested to evaluate the
administration safety of the CRD-PEG-T7/pPMEPA1.</p></sec><sec id="s0002"><label>2.</label><title>Material and methods</title><sec id="s0003"><label>2.1.</label><title>Materials</title><p>The materials used in this study were as follows: Arginine-aspartic acid peptide monomer
(sequence: RRRRRRRCDDDDDD, R7D6) and peptide T7 (sequence: HAIYPRH) (Ontores
Biotechnologies, Zhejiang, People&#x02019;s Republic of China); NHS-PEG-MAL
(&#x003b1;-maleimide-&#x003c9;-N-hydroxysuccinimidyl polyethyleneglycol, MW 3500, Nektar Therapeutics,
Huntsville, AL, USA); pPMEPA1, YOYO1-pPMEPA1 (General Biosystems, Anhui, People&#x02019;s Republic
of China); Fetal bovine serum (FBS), RPMI medium 1640 basic, Trypsin and 1% Pen Strep
(Thermo Fisher Scientific, Waltham, MA). The other chemicals and reagents were of
analytical grade.</p></sec><sec id="s0004"><label>2.2.</label><title>Cells and cell culture</title><p>Prostate carcinoma cells (LNCaP, American Type Culture Collection, Manassas, VA, USA)
were cultured in RPMI medium 1640 basic containing 10% FBS and 1% Pen Strep under 5%
CO<sub>2</sub> atmosphere at 37&#x02009;&#x000b0;C. When reaching 80&#x02013;90% confluence, the cells were
trypsinized and resuspended for further use.</p></sec><sec id="s0005"><label>2.3.</label><title>Animals</title><p>Four-week-old male BALB/c nude mice (18&#x02013;22&#x02009;g) purchased from Shanghai SLAC Laboratory
Animal Co., Ltd., (Shanghai China) were housed under standard laboratory conditions. All
animal protocols complied with the International Ethical Guideline and National Institutes
of Health Guidelines on the Care and Use of Laboratory Animals, and with the approval of
the Institutional Animal Care and Use Committee of Fujian University of Traditional
Chinese Medicine.</p></sec><sec id="s0006"><label>2.4.</label><title>Synthesis of polypeptide gene carrier</title><p>Polypeptide gene carrier was successfully synthesized by the F-mocsolid-phase synthesis
method described as our earlier study (Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>). Briefly, R7D6 monomers (arginine&#x02013;aspartic acid peptide, sequence
CRRRRRRRCDDDDDD) dissolved in 10&#x02009;mL distilled water, the <sc>l</sc>-cysteine hydrochloride
monohydrates (Cys) were added in the mixture at the molar ratios of 5:1. Followed by, the
system was added with 1% H<sub>2</sub>O<sub>2</sub> of 0.5&#x02009;mL dropwise. After 12&#x02009;h, the
acid peptide linked with disulfide bonds known as CRD was extracted and purified. Then,
CRD were reacted with NHS-PEG-MAL (MW: 3400) at the molar ratio of 1:10 in distilled water
for 6&#x02009;h to produce CRD-PEG-MAL. Finally, the conjugate was reacted with Cys-T7 at a molar
ratio of 1:5 in distilled water for 6&#x02009;h to form the final product CRD-PEG-T7. All the
reactions were conducted under room temperature.</p></sec><sec id="s0007"><label>2.5.</label><title>Preparation of the peptide T7-modified polypeptide nanoparticles</title><p>The CRD-PEG-T7 solution and pPMEPA1 (2&#x02009;&#x003bc;g) with N/P ratio of 15 was vortexed for 30&#x02009;s.
The samples were then incubated for 30&#x02009;min at room temperature to obtain
CRD-PEG-T7/pPMEPA1. In addition, R7D6/pPMEPA1, CRD-PEG-T7/YOYO1-pPMEPA1, and
R7D6/YOYO1-pPMEPA1 were prepared with the same method. The particle size and zeta
potential of CRD-PEG-T7/pPMEPA1 was measured using a Zeta-sizer Nano ZS90 (Malvern, USA).
The morphology was visualized by transmission electron microscopy (TEM, 100CXII,
Japan).</p></sec><sec id="s0008"><label>2.6.</label><title>Internalization mechanisms</title><p>Cells cultured with endocytic inhibitors or excessive T7 at different temperature were
applied to investigate the cellular uptake mechanisms of CRD-PEG-T7/pPMEPA1 (Wu et&#x000a0;al.,
<xref rid="CIT0033" ref-type="bibr">2014</xref>). LNCaP cells suspensions were incubated
into a 24-well plate at a density of 2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well for 24&#x02009;h. Then the
cell culture medium was replaced with CRD-PEG-T7/YOYO1-pPMEPA1 at 4&#x02009;&#x000b0;C,
CRD-PEG-T7/YOYO1-pPMEPA1 at 37&#x02009;&#x000b0;C, or CRD-PEG-T7/YOYO1-pPMEPA1 with excessive free T7
(100&#x02009;mM) at 37&#x02009;&#x000b0;C. After incubation for 1&#x02009;h, LNCaP cells were exposed to a fluorescent
microscope (Leica Microsystems, Wetzlar, Germany) to monitor the cellular uptake. In
addition, the cells uptake rate was detected by flow cytometry (NIKON, Japan).</p><p>Besides, LNCaP cells suspensions were incubated into a 24-well plate at a density of
2&#x02009;&#x000d7;&#x02009;10<sup>5</sup> cells per well for 24&#x02009;h. Then the cell culture medium was replaced
with the fresh serum-free RPMI 1640 containing colchicine (10&#x02009;nM), filipin (5&#x02009;mg/mL),
PhAsO (1&#x02009;mM), polylysine (5&#x02009;mg/mL) and excessive T7 (100&#x02009;mM) for 10&#x02009;min at 37&#x02009;&#x000b0;C,
respectively. Subsequently, the cells were washed with PBS and treated with 100&#x02009;nM
CRD-PEG-T7/YOYO1-pPMEPA1 complexes or R7D6-YOYO1-pPMEPA1 for another 1&#x02009;h at 37&#x02009;&#x000b0;C. The
cellular uptake was then imaged by fluorescent microscope (Leica Microsystems, Wetzlar,
Germany). The cells cultured only with CRD-PEG-T7/YOYO1-pPMEPA1 or R7D6-YOYO1-pPMEPA1 as
control. For quantitative analysis, the cells were treated with 1% Triton X-100 and
centrifuged at 3000&#x02009;rpm for 15&#x02009;min. The fluorescence intensity of the YOYO1 in the
supernatant was determined by a microplate fluorometer (LS 55, PerkinElmer Inc, Waltham,
MA, USA). Besides, the protein concentration in cell lysis fluid was quantified using
Bradford assay (Beyotime) with bovine serum albumin as a protein standard. The relative
uptake efficiency (RUE) was calculated as the following formula (Huang et&#x000a0;al., <xref rid="CIT0014" ref-type="bibr">2009</xref>). <disp-formula id="M0001"><alternatives><graphic xlink:href="IDRD_A_1709923_M0001.jpg" position="float" orientation="portrait"/><mml:math id="d1e664"><mml:mrow><mml:mtext>RUE</mml:mtext><mml:mi>&#x02009;</mml:mi><mml:mo>=</mml:mo><mml:mi>&#x02009;</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>experimental</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>fluorescent</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>intensity</mml:mtext><mml:mo>/</mml:mo><mml:mtext>mg</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>protein</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mtext>control</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>fluorescent</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>intensity</mml:mtext><mml:mo>/</mml:mo><mml:mtext>mg</mml:mtext><mml:mi>&#x000a0;</mml:mi><mml:mtext>protein</mml:mtext></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mi mathvariant="normal">&#x000d7;</mml:mi><mml:mn>100</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></alternatives></disp-formula>
</p></sec><sec id="s0009"><label>2.7.</label><title>Cells chemotaxis</title><p>Transwell assay was applied to evaluate the LNCaP migration after the cells treated with
CRD-PEG-T7/pPMEPA1, CRD-PEG-T7 and R7D6/pPMEPA1 (Zhang et&#x000a0;al., <xref rid="CIT0037" ref-type="bibr">2016</xref>). Briefly, LNCaP cells cultured with FBS-free RPMI medium 1640
basic for 24&#x02009;h and then treated with CRD-PEG-T7/pPMEPA1, R7D6/pPMEPA1 and CRD-PEG-T7 for
another 4&#x02009;h. Then the cells were cultured with FBS-free medium for another 24&#x02009;h and
digested. Followed by, the cells were added into the insert of Transwell (Matrigelfree
polycarbonate membranes, 24-well plant, pore size 8&#x02009;&#x000b5;m), while the bottom champers with
RPMI medium 1640 basis containing 10% FBS was used as cell chemotaxis. After 48&#x02009;h
incubation, the cells in the top-side were removed and the cells migrated to the bottom
side of the insert were fixed with 4% paraformaldehyde and stained with violet crystal.
Subsequently, the transwell insert member was visualized by fluorescence microscopy and
the migrated cells were counted by software Image J.</p></sec><sec id="s0010"><label>2.8.</label><title><italic>In vivo</italic> anti-tumor effect</title><p>A xenograft tumor model was established by injecting 2&#x02009;&#x000d7;&#x02009;10<sup>6</sup> LNCaP cells into
the tibia of 4-week-old male BALB/c nude mice. When the tumor volume reached about
100&#x02009;mm<sup>3</sup>, the mice were randomized into 4 groups and respectively injected
with 0.2&#x02009;mL normal saline (control), CRD-PEG-T7, R7D6/pPMEPA1, and CRD-PEG-T7/pPMEPA1
through tail vein at days 1, 3, 5, 7, and 11 (Fisher et&#x000a0;al., <xref rid="CIT0009" ref-type="bibr">2002</xref>). The first injection day was set as day 1. The dose was
equivalent to 50&#x02009;&#x003bc;g/kg of pPMEPA1. Tumor volume (<inline-formula id="ilm0001"><alternatives><inline-graphic xlink:href="IDRD_A_1709923_ILM0001.jpg"/><mml:math id="d1e768"><mml:mi>v</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>a</mml:mi><mml:msup><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></alternatives></inline-formula>
v: the tumor volume, <italic>a</italic>: the longest diameter of tumor,
<italic>b</italic>: the shortest diameter of tumor) was measured every other day. The
survival rates were recorded after administration and the tumors were surgically excised
and weighted when the mice died.</p></sec><sec id="s0011"><label>2.9.</label><title>Systemic toxicity</title><p>The systemic toxicity of CRD-PEG-T7/pPMEPA1 was evaluated by the tumor-bearing mice
weight changes and routine blood examination. The xenograft tumor model of BALB/c nude
mice was randomized into 4 groups: normal saline (control), CRD-PEG-T7, R7D6/pPMEPA1, and
CRD-PEG-T7/pPMEPA1. Then the mice were respectively injected with 0.2&#x02009;mL of the different
samples through tail vein at days 1, 3, 5, 7, and 11. Body weight was measured every other
day after administration. After the last day of administration, orbital blood was sampled
and subjected to a routine blood test. The neutrophile (Gran), red blood cell (RBC),
Hemoglobin blood (HGB), platelet (PLT), and white blood cell (WBC) count were measured
through a blood cell analyzer (ADVIA2120, Siemens, Germany).</p></sec><sec id="s0012"><label>2.10.</label><title>Histological (HE) analysis</title><p>HE analysis was carried out to study the effect of CRD-PEG-T7/pPMEPA1 on organs of the
heart, liver, spleen, lung, kidneys, and tumor. Briefly, xenograft tumor model of BALB/c
nude mice was randomized into 4 groups (<italic>n</italic>&#x02009;=&#x02009;6) and respectively injected
with 0.2&#x02009;mL normal saline (control), CRD-PEG-T7, R7D6/pPMEPA1, and CRD-PEG-T7/pPMEPA1
through tail vein at days 1, 3, 5, 7, and 11. After the last day of administration, the
mice were euthanized and the organs of the heart, liver, spleen, lung, kidneys, and tumor
were harvested. Then the samples were stained with hematoxylin and eosin (H &#x00026; E) under
the guidance of manufacturers&#x02019; standard protocol and imaged using a light microscope
(Leica, Germany).</p></sec><sec id="s0013"><label>2.11.</label><title>Statistical analysis</title><p>The results were represented as a mean of at least three experiments with the
corresponding standard deviation (SD). Statistical data were analyzed using SPSS software
version 18.0 and a statistically significant difference was denoted by the difference
probability level (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.05). <italic>t</italic>-Test and
least-significant different (LSD) were used to analyze the statistical data.</p></sec></sec><sec id="s0014"><label>3.</label><title>Results</title><sec id="s0015"><label>3.1.</label><title>Characterization of CRD-PEG-T7/pPMEPA1</title><p>The particle size, zeta potential, and morphology of the prepared CRD-PEG-T7/pPMEPA1 are
shown in <xref ref-type="fig" rid="F0001">Figure 1</xref>. The size and polydispersity
index (PDI) were 152.9&#x02009;&#x000b1;&#x02009;4.30 and 0.126&#x02009;&#x000b1;&#x02009;0.006, respectively (<xref ref-type="fig" rid="F0001">Figure 1(A)</xref>). And the zeta potential was 17.6&#x02009;&#x000b1;&#x02009;0.62 (<xref ref-type="fig" rid="F0001">Figure 1(B)</xref>). As shown in <xref ref-type="fig" rid="F0001">Figure 1(C)</xref>, the morphology of CRD-PEG-T7-pDNA was mostly spherical
and the size distribution was in accordance with the results of laser scattering
technique.</p><fig id="F0001" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>The size distribution (A); zeta potential (B); and morphology (C) of the
CRD-PEG-T7/pPMEPA1.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0001_C"/></fig></sec><sec id="s0016"><label>3.2.</label><title>Internalization mechanisms</title><p>Cell uptake at different incubation conditions is shown in <xref ref-type="fig" rid="F0002">Figure 2</xref>. The cellular uptake of CRD-PEG-T7/YOYO1-pPMEPA1 at 37&#x02009;&#x000b0;C
was significantly high than that at 4&#x02009;&#x000b0;C (<xref ref-type="fig" rid="F0002">Figure
2(A,B)</xref>). In addition, cellular uptake in the group with excessive free T7 was
lower compared with that in the CRD-PEG-T7/YOYO1-pPMEPA1 group at 37&#x02009;&#x000b0;C (<xref ref-type="fig" rid="F0002">Figure 2(B,C)</xref>). The results of cellular uptake were
consistent with the fluorescent images.</p><fig id="F0002" orientation="portrait" position="float"><label>Figure 2.</label><caption><p>The cellular uptake of CRD-PEG-T7/YOYO1-pPMEPA1 at 37&#x02009;&#x000b0;C (A), 4&#x02009;&#x000b0;C (B), with
excessive free T7 at 37&#x02009;&#x000b0;C (C), and the quantitative evaluation of the cellular uptake
in the different intribution condition (D).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0002_C"/></fig><p><xref ref-type="fig" rid="F0003">Figure 3</xref> was the results of cell uptake effect of
the LNCaP cells pretreated with different inhibitors. The fluorescence intensity in cells
treated with inhibitors was lower than that in the control group
(CRD-PEG-T7/YOYO1-pPMEPA1) in different degrees as shown in <xref ref-type="fig" rid="F0003">Figure 3(A)</xref>. Similarly, the cellular uptake of R7D6/YOYO1-pPMEPA1 was
inhibited by the most inhibitors except for the PhAsO. As shown in <xref ref-type="fig" rid="F0003">Figure 3(B)</xref>, the quantitative analysis of RUE consistent with the
results of the fluorescence microscope. The RUE of CRD-PEG-T7/YOYO1-pPMEPA1 group treated
with colchicine, cationic polylysine, filipin, PhAsO, and excessive T7 was 53.17&#x02009;&#x000b1;&#x02009;5.30%,
37.66&#x02009;&#x000b1;&#x02009;4.17%, 44.56&#x02009;&#x000b1;&#x02009;15.30%, 66.36&#x02009;&#x000b1;&#x02009;4.05%, 31.60&#x02009;&#x000b1;&#x02009;8.41%, while that of
R7D6/YOYO1-pPMEPA1 group were 66.07&#x02009;&#x000b1;&#x02009;3.73%, 44.42&#x02009;&#x000b1;&#x02009;3.23%, 44.82&#x02009;&#x000b1;&#x02009;6.23%, 91.37&#x02009;&#x000b1;&#x02009;5.11%,
59.61&#x02009;&#x000b1;&#x02009;4.38%, respectively (the RUE value of CRD-PEG-T7/YOYO1-pPMEPA1 and
R7D6/YOYO1-pPMEPA1 was both 100%).</p><fig id="F0003" orientation="portrait" position="float"><label>Figure 3.</label><caption><p>Qualitative and quantitative evaluation of cellular uptake of CRD-PEG-T7/YOYO1-
pPMEPA1 and R7D6/YOYO1-pPMEPA1: The fluorescence intensity (A) and RUE (B) of the
different groups incubated with various cell uptake inhibitors. (*** means
<italic>p</italic>&#x02009;&#x0003c;&#x02009;.001).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0003_C"/></fig></sec><sec id="s0017"><label>3.3.</label><title>Cells chemotaxis</title><p>The migration LNCaP cells stained by crystal violet and the migration cell counts were
shown in <xref ref-type="fig" rid="F0004">Figure 4</xref>. The results of microscopic
photographs and migration cells counts indicated that the effect of migration of LNCaP
cells treated with CRD-PEG-T7/pPMEPA1 was significantly inhibited compared with the
control group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01). Besides, it was significant different in the
inhibition effect between CRD-PEG-T7/pPMEPA1 and R7D6/pPMEPA1
(<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01). In addition, the counts of migrated cells of the control,
CRD-PEG-T7, R7D6/pPMEPA1, and CRD-PEG-T7/pPMEPA1 were 1333&#x02009;&#x000b1;&#x02009;135, 1128&#x02009;&#x000b1;&#x02009;103, 788&#x02009;&#x000b1;&#x02009;46,
and 94&#x02009;&#x000b1;&#x02009;18, respectively.</p><fig id="F0004" orientation="portrait" position="float"><label>Figure 4.</label><caption><p>LNCaP cells migration assay using transwell assay. (A) the microphotograph of LNCaP
cells attached to the transwell assay membrane; (B) the migrated cells count in groups
of control, CRD-PEG-T7, CRD-PEG-T7/pPMEPA1, and R7D6/pPMEPA1 (** means
<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0004_C"/></fig></sec><sec id="s0018"><label>3.4.</label><title><italic>In vivo</italic> anti-tumor effect</title><p>Nude mice bearing human transplanted prostate cancer were randomly divided into four
groups: CRD-PEG-T7, CRD-PEG-T7/pPMEPA1, R7D6/pPMEPA1, and normal saline (as control). The
survival duration profiles reflecting the anticancer effect are presented in <xref ref-type="fig" rid="F0005">Figure 5(A)</xref> and <xref rid="t0001" ref-type="table">Table 1</xref>. The results indicated that CRD-PEG-T7/pPMEPA1 and R7D6/pPMEPA1 could
effectively prolong the mice lifetime and that the antitumor effect of CRD-PEG-T7/pPMEPA1
was superior to that of the unmodified polypeptide nanoparticles
(<italic>p</italic>&#x02009;&#x0003c;&#x02009;.5). The mean survival duration of the control, CRD-PEG-T7,
CRD-PEG-T7/pPMEPA1, and R7D6/pPMEPA1 were 46.2&#x02009;days, 47.0&#x02009;days, 79.2&#x02009;days, and 60.1&#x02009;days,
respectively. The log-rank analysis showed that the survival duration in the
CRD-PEG-T7/pPMEPA1 group was significantly longer compared with the others groups
(<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01). As shown in <xref ref-type="fig" rid="F0005">Figure
5(B)</xref>, the significant suppression in tumor growth was also observed in the group
of CRD-PEG-T7/pPMEPA1. Besides, the results of the mean tumor weight were displayed in
<xref rid="t0001" ref-type="table">Table 1</xref> showed that the CRD-PEG-T7/pPMEPA1
performed sustainable suppressive effect on tumor growth.</p><fig id="F0005" orientation="portrait" position="float"><label>Figure 5.</label><caption><p>The <italic>in&#x000a0;vivo</italic> anti-tumor effect of CRD-PEG-T7/pPMEPA1, R7D6/pPMEPA1,
and CRD-PEG-T7 in LNCaP cell-derived tumor-bearing mice model. (A) The Kaplan&#x02013;Meier
survival curve; (B) The tumor volumes.</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0005_C"/></fig><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1.</label><caption><p>The <italic>in&#x000a0;vivo</italic> effect of CRD-PEG-T7/pPMEPA1 on tumor-bearing mouse
model.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Groups</th><th align="center">MST (days)</th><th align="center">Median (days)</th><th align="center">The average weight of
tumors</th><th align="center">Compared with normal
saline</th><th align="center">Compared with CRD-PEG-T7</th><th align="center">Compared with
R7D6/pPMEPA1</th></tr></thead><tbody valign="top"><tr><td align="left">Normal Saline</td><td align="char" char=".">46.2</td><td align="char" char=".">48</td><td align="char" char="&#x000b1;">1.36&#x02009;&#x000b1;&#x02009;0.15</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left">CRD-PEG-T7</td><td align="char" char=".">47.0</td><td align="char" char=".">43</td><td align="char" char="&#x000b1;">1.35&#x02009;&#x000b1;&#x02009;0.26</td><td align="center"><italic>p</italic> &#x0003e;
.05</td><td align="center">&#x02013;</td><td align="center">&#x02013;</td></tr><tr><td align="left">CRD-PEG-T7/pPMEPA1</td><td align="char" char=".">79.2</td><td align="char" char=".">79</td><td align="char" char="&#x000b1;">0.14&#x02009;&#x000b1;&#x02009;0.01</td><td align="center">**</td><td align="center">**</td><td align="center">**</td></tr><tr><td align="left">R7D6/ pPMEPA1</td><td align="char" char=".">60.1</td><td align="char" char=".">65</td><td align="char" char="&#x000b1;">0.65&#x02009;&#x000b1;&#x02009;0.19</td><td align="center">**</td><td align="center">**</td><td align="center">&#x02013;</td></tr></tbody></table><table-wrap-foot><fn id="TF1"><p>Note: **<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01 of the log-rank analysis.</p></fn><fn id="TF2"><p>Abbreviation: MST, median survival time.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0019"><label>3.5.</label><title>Systemic toxicity</title><p>As shown in <xref ref-type="fig" rid="F0006">Figure 6</xref>, the mice weight of the
CRD-PEG-T7, CRD-PEG-T7/pPMEPA1, R7D6/pPMEPA1, and control groups was monitored for 21 d.
There are no significant differences in the groups of control and CRD-PEG-T7, implying
that CRD-PEG-T7 was a safe carrier for gene therapy. In addition, the weight of
tumor-bearing mice treated with CRD-PEG-T7/pPMEPA1 and R7D6/pPMEPA1 was heavier than that
treated with normal saline and blank carriers. What&#x02019;s more, the hematological toxicity of
tumor-bearing mice treated with CRD-PEG-T7/pPMEPA1 was studied by routine blood
examination. As shown in <xref rid="t0002" ref-type="table">Table 2</xref>, the parameters
of Gran, RBC, PLT, and WBC were significantly decreased, while the HGB index was
up-regulated in the groups of polypeptide nanoparticle loading gene.</p><fig id="F0006" orientation="portrait" position="float"><label>Figure 6.</label><caption><p>The changes in the bodyweight of PCa cancer tumor-bearing mice over time
(<italic>n</italic>&#x02009;=&#x02009;10).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0006_C"/></fig><table-wrap id="t0002" orientation="portrait" position="float"><label>Table 2.</label><caption><p>The hematological parameters of the tumor-bearing mice with different treating
(<italic>n</italic>&#x02009;=&#x02009;10).</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/><col width="1*"/></colgroup><thead><tr><th align="left">Groups</th><th align="center">Gran (&#x000d7;10<sup>9</sup>/L)</th><th align="center">RBC (&#x000d7;10<sup>12</sup>/L)</th><th align="center">HGB (g/L)</th><th align="center">PLT (&#x000d7;10<sup>9</sup>/L)</th><th align="center">WBC (&#x000d7;10<sup>9</sup>/L)</th></tr></thead><tbody valign="top"><tr><td align="left">Normal saline</td><td align="char" char=".">9.69&#x02009;&#x000b1;&#x02009;1.08</td><td align="char" char=".">7.41&#x02009;&#x000b1;&#x02009;0.25</td><td align="char" char=".">132.59&#x02009;&#x000b1;&#x02009;7.49</td><td align="char" char=".">1593.04&#x02009;&#x000b1;&#x02009;352.71</td><td align="char" char=".">20.72&#x02009;&#x000b1;&#x02009;2.27</td></tr><tr><td align="left">CRD-PEG-T7</td><td align="char" char=".">9.71&#x02009;&#x000b1;&#x02009;0.19</td><td align="char" char=".">7.44&#x02009;&#x000b1;&#x02009;0.11</td><td align="char" char=".">135.16&#x02009;&#x000b1;&#x02009;6.92</td><td align="char" char=".">1590.14&#x02009;&#x000b1;&#x02009;141.79</td><td align="char" char=".">21.23&#x02009;&#x000b1;&#x02009;2.25</td></tr><tr><td align="left">R7D6/pPMEPA1</td><td align="char" char=".">9.42&#x02009;&#x000b1;&#x02009;1.97**</td><td align="char" char=".">7.24&#x02009;&#x000b1;&#x02009;1.08**</td><td align="char" char=".">149.75&#x02009;&#x000b1;&#x02009;9.98**</td><td align="char" char=".">1264.62&#x02009;&#x000b1;&#x02009;268.32**</td><td align="char" char=".">18.81&#x02009;&#x000b1;&#x02009;3.20**</td></tr><tr><td align="left">CRD-PEG-T7/ pPMEPA1</td><td align="char" char=".">9.47&#x02009;&#x000b1;&#x02009;2.18**</td><td align="char" char=".">7.19&#x02009;&#x000b1;&#x02009;0.97**</td><td align="char" char=".">143.81&#x02009;&#x000b1;&#x02009;10.07**</td><td align="char" char=".">1413.53&#x02009;&#x000b1;&#x02009;289.05**</td><td align="char" char=".">19.31&#x02009;&#x000b1;&#x02009;4.21**</td></tr></tbody></table><table-wrap-foot><fn id="TF3"><p>Note: **<italic>p</italic>&#x02009;&#x0003c;&#x02009;.01 of the variance analysis compared with the
group of normal saline.</p></fn><fn id="TF4"><p>Abbreviations: Gran: neutrophile granulocyte; RBC: red blood cell; HGB: Hemoglobin
blood; PLT: platelet; WBC: white blood cell.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s0020"><label>3.6.</label><title>Histological (HE) analysis</title><p>The HE microscopic pictures of the heart, liver, spleen, lung, kidneys, and tumor of mice
treated with normal saline, CRD-PEG-T7, R7D6/pPMEPA1, and CRD-PEG-T7/pPMEPA1 are shown in
<xref ref-type="fig" rid="F0007">Figure 7</xref>. It was obvious that the cells were
necrosis, fibrosis with hemorrhage in the tumor tissue treated with CRD-PRE-T7/pPMEPA1
compared with normal saline. Besides, in the four groups, there were no obvious
abnormalities, lesions or degenerations in visceral organs, indicating the
CRD-PRE-T7/pPMEPA1 did not induce any organotoxicity.</p><fig id="F0007" orientation="portrait" position="float"><label>Figure 7.</label><caption><p>Histopathological photomicrographs of tumor-bearing mice heart, liver spleen, lung,
kidneys, and tumor. (&#x000d7;200).</p></caption><graphic content-type="color" xlink:href="IDRD_A_1709923_F0007_C"/></fig></sec></sec><sec id="s0021"><label>4.</label><title>Discussion</title><p>Peptide T7-modified vectors (CRD-PEG-T7) prepared using the F-mocsolid-phase synthesis
method was evaluated as gene delivery (CRD-PEG-T7/pPMEPA1) for BMPCa treatment. The
morphology of the nanoparticles was uniform with small particle size distribution and
positive charge. Our previous reported that the developed CRD-PEG-T7/pPMEPA1 was
characteristic of admirable gene transfection and targeting efficacy with excellent
biocompatibility (Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>).</p><p>LNCaP cells cultured with different incubation condition, excessive T7, and endocytic
inhibitors were applied to investigate the cellular uptake mechanisms of CRD-PEG-T7/pPMEPA1.
The results of cellular uptake at different incubation temperature indicated that the
cellular uptake of CRD-PRG-T7/pPMEPA1 was characterized by energy dependence. Besides,
early-stage, excessive T7 could inhibit the cellular uptake of CRD-PEG-T7 competitively. In
addition, colchicine inhibits the macropinocytosis and cationic polylysine is an inhibitor
to uptake the cationic NPs (Wu et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2014</xref>;
Voltan et&#x000a0;al., <xref rid="CIT0032" ref-type="bibr">2017</xref>). The caveolae-mediated
process and clathrin-dependent endocytosis was blocked by flipin and PhAsO, respectively
(Kim et&#x000a0;al., <xref rid="CIT0015" ref-type="bibr">2007</xref>; Liu et&#x000a0;al., <xref rid="CIT0021" ref-type="bibr">2018b</xref>). The results showed that the cell uptake of
CRD-PEG-T7/YOYO1-pPMEPA1 was proportional to energy and inversely to the presence of T7,
which reflected that T7 competitively uptake with CRD-PEG-T7/pPMEPA1. In addition, LNCaP
uptake of CRD-PEG-T7/pPMEPA1 was depending on macropinocytosis, caveolae-mediated
endocytosis, and clathrin-dependent endocytosis (<xref ref-type="fig" rid="F0003">Figure
3</xref>). These results indicated that the mechanisms of receptor and adsorptive-mediated
might contribute to the cellular uptake of CRD-PEG-T7/pPMEPA1 (Huang et&#x000a0;al., <xref rid="CIT0014" ref-type="bibr">2009</xref>; Wu et&#x000a0;al., <xref rid="CIT0033" ref-type="bibr">2014</xref>).</p><p>Cell migration assay plays a central role in the evaluation of cancer migration. And the
cell culture medium containing FBS often was used as chemokines (Qiang et&#x000a0;al., <xref rid="CIT0028" ref-type="bibr">2019</xref>). The results of transwell assay indicated that
the CRD-PEG-T7/pPMEPA1 could significantly inhibit the LNCaP migration compared with the
unmodified polypeptide nanoparticles R7D6/pPMEPA1, while the blank carrier CRD-PEG-T7 same
as control group has no inhibition of migration. The results were consistent with the
previous report that the pPMEPA1 could restrain the DU145 cells migration and the reduce
gene expression followed by lower tumor progression (Feng et&#x000a0;al., <xref rid="CIT0008" ref-type="bibr">2016</xref>; Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>).
Besides, the difference between the groups of CRD-PEG-T7/pPMEPA1 and R7D6/pPMEPA1 might be
due to the high cell uptake of the nanoparticles modified by the peptide T7 showed in <xref ref-type="fig" rid="F0004">Figure 4</xref>.</p><p>The results of <italic>in&#x000a0;vivo</italic> anti-tumor indicated that CRD-PEG-T7/pPMEPA1 could
prolong the median survival time and inhibit the tumor growth with the smallest tumor volume
in the human PCa mouse model (<xref ref-type="fig" rid="F0005">Figure 5</xref> and <xref rid="t0001" ref-type="table">Table 1</xref>). The polypeptide nanoparticle modified by the
peptide T7 loading pPMEPA1 genes was successfully designed to target tumor and blocked the
pathways involved in PCa development, potentially promoting the anti-tumor effect (Fournier
et&#x000a0;al., <xref rid="CIT0010" ref-type="bibr">2015</xref>; Sharad et&#x000a0;al., <xref rid="CIT0029" ref-type="bibr">2014</xref>; Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>).</p><p>The results of systemic toxicity showed that CRD-PEG-T7/pPMEPA1 were well biocompatibility.
There was no significant fluctuation in body weight among the four groups (<xref ref-type="fig" rid="F0006">Figure 6</xref>). However, the humor-bearing mice treated with
normal saline and CRD-PEG-T7 were skinny though the weight was similar to the other mice
owing to the growing tumor volume (Liu et&#x000a0;al., <xref rid="CIT0020" ref-type="bibr">2018a</xref>). Besides, the blood parameters of Gran, RBC, PLT, WBC were decreased
compared with the control group (<xref rid="t0002" ref-type="table">Table 2</xref>),
indicating that the inflammation and tissue impairment was improved (El-Hag &#x00026; Clark,
<xref rid="CIT0007" ref-type="bibr">1987</xref>; Gay &#x00026; Felding-Habermann, <xref rid="CIT0011" ref-type="bibr">2011</xref>; Moreel et&#x000a0;al., <xref rid="CIT0024" ref-type="bibr">2014</xref>; Paramanathan et&#x000a0;al., <xref rid="CIT0027" ref-type="bibr">2014</xref>; Arthur et&#x000a0;al., <xref rid="CIT0002" ref-type="bibr">2018</xref>). What&#x02019;s
more, the up-regulated HGB demonstrated that the anemia symptoms in tumor-bearing mice were
effectively improved after treating with CRD-PEG-T7/pPMEPA1 (Beer et&#x000a0;al., <xref rid="CIT0004" ref-type="bibr">2006</xref>). Furthermore, the pathological HE analysis of
tumor indicated (<xref ref-type="fig" rid="F0006">Figure 6</xref>) that CRD-PEG-T7/pPMEPA1
could enhance cell necrosis, fibrosis with hemorrhage (Li et&#x000a0;al., <xref rid="CIT0018" ref-type="bibr">2018</xref>; Yang et&#x000a0;al., <xref rid="CIT0036" ref-type="bibr">2018</xref>).
The HE photographs of heart, liver, spleen, lung and kidney indicated that
CRD-PEG-T7/pPMEPA1 did not induced any physiological function impact compared with the
control group (Lu et&#x000a0;al., <xref rid="CIT0022" ref-type="bibr">2018</xref>). The results
implied that the DNA delivery vectors of CRD-PEG-T7 are a safe and effective treatment agent
for BMCPa.</p></sec><sec id="s0022"><label>5.</label><title>Conclusion</title><p>To the best of our knowledge, this is the first study on the PCa cells uptake mechanisms,
anticancer effect <italic>in&#x000a0;vivo</italic> and safety evaluation of the peptide T7
modified-polypeptide nanoparticles for delivery gene (CRD-PEG-T7/pPMEPA1). The LNCaP cells
uptake of T7 modified NPs by endocytic processes, depending on macropinocytosis, caveolae,
clathrin, the cationic vectors nanoparticles. Besides, CRD-PEG-T7/pPMEPA1 could
significantly inhibit LNCaP cells migration in&#x000a0;vitro. In addition, the prepared gene complex
performed significant anti-tumor effect <italic>in&#x000a0;vivo</italic> without inducing impairment
to normal tissues. In conclusion, this research proposes a prototype of the safe and
effective carrier for delivery DNA to PCa cells, which could be a promising stratagem for
treating BMPCa.</p></sec></body><back><sec id="s0023"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the authors.</p></sec><ref-list><title>References</title><ref id="CIT0001"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amalia</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Abdelaziz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Puteri</surname><given-names>MU</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2019</year>). <article-title>TMEPAI/PMEPA1 inhibits Wnt signaling by regulating
&#x003b2;-catenin stability and nuclear accumulation in triple negative breast cancer
cells</article-title>. <source>Cell Signal</source>
<volume>59</volume>, <fpage>24</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">30890370</pub-id></mixed-citation></ref><ref id="CIT0002"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arthur</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Williams</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Garmo</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018</year>). <article-title>Serum inflammatory markers in relation to prostate
cancer severity and death in the Swedish AMORIS study</article-title>. <source>Int J
Cancer</source>
<volume>142</volume>:<fpage>2254</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">29322512</pub-id></mixed-citation></ref><ref id="CIT0003"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Athie</surname><given-names>A</given-names></name>,
<name name-style="western"><surname>Arce-Gallego</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gonzalez</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2019</year>). <article-title>Targeting DNA repair defects for precision medicine
in prostate cancer</article-title>. <source>Curr Oncol Rep</source>
<volume>21</volume>:<fpage>42</fpage>.<pub-id pub-id-type="pmid">30919167</pub-id></mixed-citation></ref><ref id="CIT0004"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beer</surname><given-names>TM</given-names></name>, <name name-style="western"><surname>Tangen</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Bland</surname><given-names>LB</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2006</year>). <article-title>The prognostic value of hemoglobin change after
initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer:
a multivariate analysis of Southwest Oncology Group Study 8894</article-title>.
<source>Cancer</source>
<volume>107</volume>:<fpage>489</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">16804926</pub-id></mixed-citation></ref><ref id="CIT0005"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bubendorf</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sch&#x000f6;pfer</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Wagner</surname><given-names>U</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2000</year>). <article-title>Metastatic patterns of prostate cancer: an autopsy
study of 1,589 patients</article-title>. <source>Hum Pathol</source>
<volume>31</volume>:<fpage>578</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">10836297</pub-id></mixed-citation></ref><ref id="CIT0006"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donkor</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Sarkar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Savage</surname><given-names>PA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2011</year>). <article-title>T cell surveillance of oncogene-induced prostate
cancer is impeded by T cell-derived TGF-&#x003b2;1 cytokine</article-title>.
<source>Immunity</source>
<volume>35</volume>:<fpage>123</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">21757379</pub-id></mixed-citation></ref><ref id="CIT0007"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Hag</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>RA</given-names></name></person-group> (<year>1987</year>).
<article-title>Immunosuppression by activated human neutrophils. Dependence on the
myeloperoxidase system</article-title>. <source>J Immunol</source>
<volume>139</volume>:<fpage>2406</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">2821114</pub-id></mixed-citation></ref><ref id="CIT0008"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Fan</surname><given-names>B</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2016</year>). <article-title>miR-19a-3p targets PMEPA1 and induces prostate
cancer cell proliferation, migration and invasion</article-title>. <source>Mol Med
Rep</source>
<volume>13</volume>:<fpage>4030</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">27035427</pub-id></mixed-citation></ref><ref id="CIT0009"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisher</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Schmitt</surname><given-names>JF</given-names></name>, <name name-style="western"><surname>Howard</surname><given-names>ML</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2002</year>). <article-title>An <italic>in&#x000a0;vivo</italic> model of prostate
carcinoma growth and invasion in bone</article-title>. <source>Cell Tissue Res</source>
<volume>307</volume>:<fpage>337</fpage>&#x02013;<lpage>45</lpage>.<pub-id pub-id-type="pmid">11904770</pub-id></mixed-citation></ref><ref id="CIT0010"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Juarez</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>G</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2015</year>). <article-title>The TGF-beta signaling regulator PMEPA1 suppresses
prostate cancer metastases to bone</article-title>. <source>Cancer Cell</source>
<volume>27</volume>:<fpage>809</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">25982816</pub-id></mixed-citation></ref><ref id="CIT0011"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gay</surname><given-names>LJ</given-names></name>,
<name name-style="western"><surname>Felding-Habermann</surname><given-names>B</given-names></name></person-group> (<year>2011</year>).
<article-title>Contribution of platelets to tumour metastasis</article-title>.
<source>Nat Rev Cancer</source>
<volume>11</volume>:<fpage>123</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">21258396</pub-id></mixed-citation></ref><ref id="CIT0012"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2014</year>). <article-title>Murine double minute 2 siRNA and wild-type p53 gene
therapy interact positively with zinc on prostate tumours in&#x000a0;vitro and
<italic>in&#x000a0;vivo</italic></article-title>. <source>Eur J Cancer</source>
<volume>50</volume>:<fpage>1184</fpage>&#x02013;<lpage>94</lpage>.<pub-id pub-id-type="pmid">24447832</pub-id></mixed-citation></ref><ref id="CIT0013"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halabi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Kelly</surname><given-names>WK</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>H</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2016</year>). <article-title>Meta-analysis evaluating the impact of site of
metastasis on overall survival in men with castration-resistant prostate
cancer</article-title>. <source>JCO</source>
<volume>34</volume>:<fpage>1652</fpage>&#x02013;<lpage>9</lpage>.</mixed-citation></ref><ref id="CIT0014"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ke</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Han</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2009</year>). <article-title>Brain-targeting mechanisms of lactoferrin-modified
DNA-loaded nanoparticles</article-title>. <source>J Cereb Blood Flow Metab</source>
<volume>29</volume>:<fpage>1914</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">19654588</pub-id></mixed-citation></ref><ref id="CIT0015"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Gil</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Andrieux</surname><given-names>K</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2007</year>). <article-title>Low-density lipoprotein receptor-mediated
endocytosis of PEGylated nanoparticles in rat brain endothelial cells</article-title>.
<source>Cell Mol Life Sci</source>
<volume>64</volume>:<fpage>356</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">17256088</pub-id></mixed-citation></ref><ref id="CIT0016"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>TI</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SW</given-names></name></person-group> (<year>2010</year>).
<article-title>A guanidinylated bioreducible polymer with high nuclear localization
ability for gene delivery systems</article-title>. <source>Biomaterials</source>
<volume>31</volume>:<fpage>1798</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">19854504</pub-id></mixed-citation></ref><ref id="CIT0017"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Kroon</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Narcisi</surname><given-names>R</given-names></name>, <name name-style="western"><surname>van den
Akker</surname><given-names>GG</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2017</year>). <article-title>SMAD3 and SMAD4 have a more dominant role than SMAD2
in TGF&#x003b2;-induced chondrogenic differentiation of bone marrow-derived mesenchymal stem
cells</article-title>. <source>Sci Rep</source>
<volume>7</volume>:<fpage>43164</fpage>.<pub-id pub-id-type="pmid">28240243</pub-id></mixed-citation></ref><ref id="CIT0018"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018</year>). <article-title>A33 antibody-functionalized exosomes for targeted
delivery of doxorubicin against colorectal cancer</article-title>.
<source>Nanomedicine</source>
<volume>14</volume>:<fpage>1973</fpage>&#x02013;<lpage>85</lpage>.<pub-id pub-id-type="pmid">29935333</pub-id></mixed-citation></ref><ref id="CIT0019"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Lok</surname><given-names>MC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2006</year>). <article-title>Linear poly(amido amine)s with secondary and
tertiary amino groups and variable amounts of disulfide linkages: synthesis and in&#x000a0;vitro
gene transfer properties</article-title>. <source>J Control Release</source>
<volume>116</volume>:<fpage>130</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">17079046</pub-id></mixed-citation></ref><ref id="CIT0020"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Du</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Khan</surname><given-names>AR</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018a</year>). <article-title>Redox/enzyme sensitive chondroitin sulfate-based
self-assembled nanoparticles loading docetaxel for the inhibition of metastasis and
growth of melanoma</article-title>. <source>Carbohydr Polym</source>
<volume>184</volume>:<fpage>82</fpage>&#x02013;<lpage>93</lpage>.<pub-id pub-id-type="pmid">29352946</pub-id></mixed-citation></ref><ref id="CIT0021"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018b</year>). <article-title>Biodistribution, activation, and retention of
proinsulin-transferrin fusion protein in the liver: mechanism of liver-targeting as an
insulin prodrug</article-title>. <source>J Control Release</source>
<volume>275</volume>:<fpage>186</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">29471040</pub-id></mixed-citation></ref><ref id="CIT0022"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018</year>). <article-title>Peptide T7-modified polypeptide with disulfide bonds
for targeted delivery of plasmid DNA for gene therapy of prostate
cancer</article-title>. <source>Int J Nanomed</source>
<volume>13</volume>:<fpage>6913</fpage>&#x02013;<lpage>27</lpage>.</mixed-citation></ref><ref id="CIT0023"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miyahira</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Soule</surname><given-names>HR</given-names></name></person-group> (<year>2019</year>).
<article-title>The 25th Annual Prostate Cancer Foundation Scientific Retreat
Report</article-title>. <source>Prostate</source>
<volume>79</volume>:<fpage>1363</fpage>&#x02013;<lpage>486</lpage>.</mixed-citation></ref><ref id="CIT0024"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreel</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Allaire</surname><given-names>J</given-names></name>, <name name-style="western"><surname>L&#x000e9;ger</surname><given-names>C</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2014</year>). <article-title>Prostatic and dietary omega-3 fatty acids and
prostate cancer progression during active surveillance</article-title>. <source>Cancer
Prev Res</source>
<volume>7</volume>:<fpage>766</fpage>&#x02013;<lpage>76</lpage>.</mixed-citation></ref><ref id="CIT0025"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nakazawa</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Paller</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kyprianou</surname><given-names>N</given-names></name></person-group> (<year>2017</year>).
<article-title>Mechanisms of therapeutic resistance in prostate cancer</article-title>.
<source>Curr Oncol Rep</source>
<volume>19</volume>:<fpage>13</fpage>.<pub-id pub-id-type="pmid">28229393</pub-id></mixed-citation></ref><ref id="CIT0026"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nyquist</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>PS</given-names></name></person-group> (<year>2017</year>).
<article-title>Anti-depressant therapy brightens the outlook for prostate cancer bone
metastases</article-title>. <source>Cancer Cell</source>
<volume>31</volume>:<fpage>303</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">28292431</pub-id></mixed-citation></ref><ref id="CIT0027"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paramanathan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Saxena</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Morris</surname><given-names>DL</given-names></name></person-group> (<year>2014</year>).
<article-title>A systematic review and meta-analysis on the impact of pre-operative
neutrophil lymphocyte ratio on long term outcomes after curative intent resection of
solid tumours</article-title>. <source>Surg Oncol</source>
<volume>23</volume>:<fpage>31</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">24378193</pub-id></mixed-citation></ref><ref id="CIT0028"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qiang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Cai</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2019</year>). <article-title>A novel macrophage-mediated biomimetic delivery
system with NIR-triggered release for prostate cancer therapy</article-title>. <source>J
Nanobiotechnol</source>
<volume>17</volume>:<fpage>83</fpage>.</mixed-citation></ref><ref id="CIT0029"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharad</surname><given-names>S</given-names></name>,
<name name-style="western"><surname>Ravindranath</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Haffner</surname><given-names>MC</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2014</year>). <article-title>Methylation of the PMEPA1 gene, a negative regulator
of the androgen receptor in prostate cancer</article-title>.
<source>Epigenetics</source>
<volume>9</volume>:<fpage>918</fpage>&#x02013;<lpage>27</lpage>.<pub-id pub-id-type="pmid">24694733</pub-id></mixed-citation></ref><ref id="CIT0030"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Siegel</surname><given-names>RL</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Jemal</surname><given-names>A</given-names></name></person-group> (<year>2019</year>).
<article-title>Cancer statistics, 2019</article-title>. <source>CA A Cancer J
Clin</source>
<volume>69</volume>:<fpage>7</fpage>&#x02013;<lpage>34</lpage>.</mixed-citation></ref><ref id="CIT0031"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Singha</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Yeh</surname><given-names>IT</given-names></name>,
<name name-style="western"><surname>Venkatachalam</surname><given-names>MA</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2010</year>). <article-title>Transforming growth factor-beta (TGF-beta)-inducible
gene TMEPAI converts TGF-beta from a tumor suppressor to a tumor promoter in breast
cancer</article-title>. <source>Cancer Res</source>
<volume>70</volume>:<fpage>6377</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">20610632</pub-id></mixed-citation></ref><ref id="CIT0032"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voltan</surname><given-names>AR</given-names></name>, <name name-style="western"><surname>Alarcon</surname><given-names>KM</given-names></name>,
<name name-style="western"><surname>Fusco-Almeida</surname><given-names>AM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2017</year>). <article-title>Highlights in endocytosis of nanostructured
systems</article-title>. <source>Curr Med Chem</source>
<volume>24</volume>:<fpage>1909</fpage>&#x02013;<lpage>29</lpage>.<pub-id pub-id-type="pmid">28201970</pub-id></mixed-citation></ref><ref id="CIT0033"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Tai</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>Q</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2014</year>). <article-title>Study on the prostate cancer-targeting mechanism of
aptamer-modified nanoparticles and their potential anticancer effect
<italic>in&#x000a0;vivo</italic></article-title>. <source>Int J Nanomed</source>
<volume>9</volume>:<fpage>5431</fpage>&#x02013;<lpage>40</lpage>.</mixed-citation></ref><ref id="CIT0034"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>T</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2010</year>). <article-title>TMEPAI, a transmembrane TGF-beta-inducible protein,
sequesters Smad proteins from active participation in TGF-beta
signaling</article-title>. <source>Mol Cell</source>
<volume>37</volume>:<fpage>123</fpage>&#x02013;<lpage>34</lpage>.<pub-id pub-id-type="pmid">20129061</pub-id></mixed-citation></ref><ref id="CIT0035"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Hirata</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shiraki</surname><given-names>M</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2019</year>). <article-title>Prostate transmembrane protein androgen induced 1 is
induced by activation of osteoclasts and regulates bone resorption</article-title>.
<source>Faseb J</source>
<volume>33</volume>:<fpage>4365</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">30557043</pub-id></mixed-citation></ref><ref id="CIT0036"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Shi</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Ji</surname><given-names>J</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2018</year>). <article-title>Development of redox-responsive theranostic
nanoparticles for near-infrared fluorescence imaging-guided photodynamic/chemotherapy of
tumor</article-title>. <source>Drug Deliv</source>
<volume>25</volume>:<fpage>780</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">29542333</pub-id></mixed-citation></ref><ref id="CIT0037"><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Barrios</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Alani</surname><given-names>RM</given-names></name>, <etal>et&#x000a0;al.</etal></person-group>
(<year>2016</year>). <article-title>A microfluidic transwell to study
chemotaxis</article-title>. <source>Exp Cell Res</source>
<volume>342</volume>:<fpage>159</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">26988422</pub-id></mixed-citation></ref></ref-list></back></article>